Case report: Myocarditis in congenital STAT1 gain-of function.
STAT1 GOF
chronic mucocutaneous candidiasis
infectious susceptibility
myocarditis
primary immunodeficiencies
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
11
2022
accepted:
07
03
2023
medline:
7
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Autosomal dominant Signal transducer and activator of transcription 1 (STAT1) gain-of-function (GOF) mutations result in an inborn error of immunity characterized by chronic mucocutaneous candidiasis, recurrent viral and bacterial infections, and diverse autoimmune manifestations. Current treatment consists of chronic antifungal therapy, antibiotics for concomitant infections, and immunosuppressive therapy in case of autoimmune diseases. More recently, treatment with Janus kinases 1 and 2 (JAK1/2) inhibitors have shown promising yet variable results. We describe a STAT1 GOF patient with an incidental finding of elevated cardiac troponins, leading to a diagnosis of a longstanding, slowly progressive idiopathic myocarditis, attributed to STAT1 GOF. Treatment with a JAK-inhibitor (baricitinib) mitigated cardiac inflammation on MRI but was unable to alter fibrosis, possibly due to the diagnostic and therapeutic delay, which finally led to fatal arrhythmia. Our case illustrates that myocarditis could be part of the heterogeneous disease spectrum of STAT1 GOF. Given the insidious presentation in our case, a low threshold for cardiac evaluation in STAT1 GOF patients seems warranted.
Identifiants
pubmed: 37020552
doi: 10.3389/fimmu.2023.1095595
pmc: PMC10067556
doi:
Substances chimiques
STAT1 protein, human
0
STAT1 Transcription Factor
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1095595Informations de copyright
Copyright © 2023 Staels, Roosens, Giovannozzi, Moens, Bogaert, Iglesias-Herrero, Gijsbers, Bossuyt, Frans, Liston, Humblet-Baron, Meyts, Van Aelst and Schrijvers.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur Heart J. 2007 Dec;28(24):3076-93
pubmed: 17959624
N Engl J Med. 2009 Apr 9;360(15):1526-38
pubmed: 19357408
J Allergy Clin Immunol. 2018 Nov;142(5):1665-1669
pubmed: 30092289
Circ Genom Precis Med. 2022 Dec;15(6):e003704
pubmed: 36264615
J Oncol Pharm Pract. 2020 Aug 11;:1078155220947141
pubmed: 32781887
J Allergy Clin Immunol. 2015 Feb;135(2):551-3
pubmed: 25662309
J Biol Chem. 2010 Jul 23;285(30):23208-23
pubmed: 20472559
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35383117
J Am Coll Cardiol. 2020 Jun 9;75(22):2753-2765
pubmed: 32498802
Transpl Immunol. 2022 Jun;72:101598
pubmed: 35381344
J Allergy Clin Immunol. 2018 Jul;142(1):328-330.e2
pubmed: 29729898
Heart Rhythm. 2019 Nov;16(11):e301-e372
pubmed: 31078652
Front Immunol. 2021 Feb 17;12:632997
pubmed: 33679782
J Clin Immunol. 2020 Nov;40(8):1065-1081
pubmed: 32852681
Blood. 2016 Jun 23;127(25):3154-64
pubmed: 27114460
JACC Heart Fail. 2022 Oct;10(10):714-727
pubmed: 36175056
Eur J Heart Fail. 2016 Aug;18(8):891-975
pubmed: 27207191
J Clin Immunol. 2022 Jul;42(5):1071-1082
pubmed: 35486339
Front Immunol. 2020 Jun 09;11:1114
pubmed: 32582194
Eur Heart J. 2013 Sep;34(33):2636-48, 2648a-2648d
pubmed: 23824828
Mayo Clin Proc. 2002 Jan;77(1):92-6
pubmed: 11795251